Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (DE:GIS)
XETRA:GIS
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.75Last Year’s EPS
1.8Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: 0.71%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong growth in the HIV and liver disease segments, successful clinical trials, and promising product launches, contrasted by declines in overall product sales, Veclury, and oncology due to COVID-19 dynamics and competitive pressures. The company's strategic focus on pipeline and market expansion is promising but faces market challenges.Company Guidance
During the Gilead Sciences, Inc. First Quarter 2025 Earnings Conference Call, the company provided comprehensive guidance, highlighting key metrics and strategic initiatives. Total product sales, excluding Veclury, reached $6.3 billion, marking a 4% year-over-year increase, primarily driven by strong performance in the HIV segment, which grew by 6%. Sales of Biktarvy, a leading HIV treatment, rose by 7%, while Descovy sales surged 38% year over year. The company reported a decline in total product sales to $6.6 billion, down 1% year-over-year, due to a decrease in Veclury sales as COVID-19 hospitalizations fell. Despite this, Gilead maintained a robust 85% product gross margin and a strong operating margin of 43%. Looking ahead, Gilead anticipates continued growth with the potential launch of lenacapavir for PrEP, anetocel for multiple myeloma, and Trodelvy for breast cancer, while maintaining a focus on disciplined expense management and strategic investments in its pipeline. The company reaffirmed its full-year guidance, projecting total product sales between $28.2 to $28.6 billion and non-GAAP diluted EPS of $7.70 to $8.10.HIV Business Growth
HIV sales increased by 6% year over year, driven by higher average realized price and demand. Biktarvy sales were up 7% year over year, highlighting strong demand-led volume growth.
Livedelzi Market Entry Success
Livedelzi continues its strong launch momentum, with $40 million in sales in its second full quarter, capturing about a third of the market in its category.
Trodelvy Phase III Success
Trodelvy plus pembrolizumab demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the phase III ASCENT-04 trial for first-line PD-L1 positive metastatic triple-negative breast cancer.
Positive Operating Margins
The company reported strong operating margin and earnings per share, reflecting effective expense management.
Strong Cell Therapy Outlook
Anetocel remains on track to potentially launch in 2026 for relapsed refractory multiple myeloma, with promising clinical profiles and manufacturing capabilities.
Improvements in Liver Disease Sales
Sales increased by 3% year over year, driven by demand across PBC, HBV, and HDV, despite lower average realized prices for HCV products in the US.
DE:GIS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:GIS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 24, 2025 | €94.56 | €90.40 | -4.40% |
Feb 11, 2025 | €91.70 | €99.11 | +8.08% |
Nov 06, 2024 | €84.01 | €88.57 | +5.43% |
Aug 08, 2024 | €67.46 | €65.74 | -2.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Gilead Sciences (DE:GIS) report earnings?
Gilead Sciences (DE:GIS) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Gilead Sciences (DE:GIS) earnings time?
Gilead Sciences (DE:GIS) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Gilead Sciences stock?
The P/E ratio of Gilead Sciences is N/A.
What is DE:GIS EPS forecast?
DE:GIS EPS forecast for the fiscal quarter 2025 (Q2) is 1.75.